FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia

G. Specchia, D. Pastore, P. Carluccio, A. Liso, A. Mestice, R. Rizzi, L. Ciuffreda, G. Pietrantuono, V. Liso

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Relapsed or refractory adult acute lymphoblastic leukemias (ALL) have poor prognosis. The strategy for treating these patients is through reinduction chemotherapy followed by allogeneic stem cell transplantation, provided that the toxicity of the salvage regimen is acceptable. Twenty three patients with relapsed/refractory adult ALL were treated with fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA). Five patients had primary refractory disease, and 18 were in first relapse. Nine (39.1%) patients achieved complete remission (CR) following salvage therapy, whereas 13 (56.5%) patients were refractory, and one patient died in aplasia due to infection. In patients achieving remission, the median time to reach absolute neutrophil count (ANC) more than 0.5×109/l and 1×109/l was 20 (range 16-25) and 24 (range 20-28) days from the start of chemotherapy, respectively. Platelet levels of more than 20×109/l and 100×109/l were achieved in a median time of 23 (range 19-25) and 33 (range 28-39) days, respectively. Fever more than 38.5°C was observed in 18 of 23 patients (78.2%), 13 had fever of unknown origin, and 5 had documented infections. Nonhematological side effects, consisting mainly of mucositis (18/23 or 78.2%) and transient liver toxicity increase (10/23 or 43.4%), were generally tolerated. All nine patients who achieved CR received a second course with FLAG-IDA, and seven patients underwent allogeneic stem cell transplantation (four from a matched donor, one from a mismatched donor, and two from an unrelated donor), while two did not reach that stage due to early relapse from CR. The median overall survival (OS) for all 23 patients was 4.5 (range 1-38) months; for the nine responders, the disease-free survival (DFS) and the OS were 6 (range 3-38) and 9 (7-38) months, respectively; the seven patients who received allogeneic stem cell transplantation had a DFS of 10 (range 7-38) months. In our experience, FLAG-IDA is a well-tolerated regimen in relapsed/refractory ALL patients; the toxicity is acceptable, enabling patients who have achieved CR to receive allogeneic transplantation.

Original languageEnglish
Pages (from-to)792-795
Number of pages4
JournalAnnals of Hematology
Volume84
Issue number12
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Therapeutics
Stem Cell Transplantation
Disease-Free Survival
Tissue Donors
Idarubicin
Fever of Unknown Origin
Recurrence
Drug Therapy
Salvage Therapy
Unrelated Donors
Mucositis
Survival
Cytarabine
Homologous Transplantation
Granulocyte Colony-Stimulating Factor
Infection
Neutrophils
Fever
Blood Platelets

Keywords

  • Acute lymphoblastic leukemia
  • FLAG-IDA
  • Refractory
  • Relapsed

ASJC Scopus subject areas

  • Hematology

Cite this

Specchia, G., Pastore, D., Carluccio, P., Liso, A., Mestice, A., Rizzi, R., ... Liso, V. (2005). FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Annals of Hematology, 84(12), 792-795. https://doi.org/10.1007/s00277-005-1090-9

FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. / Specchia, G.; Pastore, D.; Carluccio, P.; Liso, A.; Mestice, A.; Rizzi, R.; Ciuffreda, L.; Pietrantuono, G.; Liso, V.

In: Annals of Hematology, Vol. 84, No. 12, 12.2005, p. 792-795.

Research output: Contribution to journalArticle

Specchia, G, Pastore, D, Carluccio, P, Liso, A, Mestice, A, Rizzi, R, Ciuffreda, L, Pietrantuono, G & Liso, V 2005, 'FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia', Annals of Hematology, vol. 84, no. 12, pp. 792-795. https://doi.org/10.1007/s00277-005-1090-9
Specchia G, Pastore D, Carluccio P, Liso A, Mestice A, Rizzi R et al. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Annals of Hematology. 2005 Dec;84(12):792-795. https://doi.org/10.1007/s00277-005-1090-9
Specchia, G. ; Pastore, D. ; Carluccio, P. ; Liso, A. ; Mestice, A. ; Rizzi, R. ; Ciuffreda, L. ; Pietrantuono, G. ; Liso, V. / FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. In: Annals of Hematology. 2005 ; Vol. 84, No. 12. pp. 792-795.
@article{e5bf9266b716444b9b03dee4aa7a1712,
title = "FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia",
abstract = "Relapsed or refractory adult acute lymphoblastic leukemias (ALL) have poor prognosis. The strategy for treating these patients is through reinduction chemotherapy followed by allogeneic stem cell transplantation, provided that the toxicity of the salvage regimen is acceptable. Twenty three patients with relapsed/refractory adult ALL were treated with fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA). Five patients had primary refractory disease, and 18 were in first relapse. Nine (39.1{\%}) patients achieved complete remission (CR) following salvage therapy, whereas 13 (56.5{\%}) patients were refractory, and one patient died in aplasia due to infection. In patients achieving remission, the median time to reach absolute neutrophil count (ANC) more than 0.5×109/l and 1×109/l was 20 (range 16-25) and 24 (range 20-28) days from the start of chemotherapy, respectively. Platelet levels of more than 20×109/l and 100×109/l were achieved in a median time of 23 (range 19-25) and 33 (range 28-39) days, respectively. Fever more than 38.5°C was observed in 18 of 23 patients (78.2{\%}), 13 had fever of unknown origin, and 5 had documented infections. Nonhematological side effects, consisting mainly of mucositis (18/23 or 78.2{\%}) and transient liver toxicity increase (10/23 or 43.4{\%}), were generally tolerated. All nine patients who achieved CR received a second course with FLAG-IDA, and seven patients underwent allogeneic stem cell transplantation (four from a matched donor, one from a mismatched donor, and two from an unrelated donor), while two did not reach that stage due to early relapse from CR. The median overall survival (OS) for all 23 patients was 4.5 (range 1-38) months; for the nine responders, the disease-free survival (DFS) and the OS were 6 (range 3-38) and 9 (7-38) months, respectively; the seven patients who received allogeneic stem cell transplantation had a DFS of 10 (range 7-38) months. In our experience, FLAG-IDA is a well-tolerated regimen in relapsed/refractory ALL patients; the toxicity is acceptable, enabling patients who have achieved CR to receive allogeneic transplantation.",
keywords = "Acute lymphoblastic leukemia, FLAG-IDA, Refractory, Relapsed",
author = "G. Specchia and D. Pastore and P. Carluccio and A. Liso and A. Mestice and R. Rizzi and L. Ciuffreda and G. Pietrantuono and V. Liso",
year = "2005",
month = "12",
doi = "10.1007/s00277-005-1090-9",
language = "English",
volume = "84",
pages = "792--795",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia

AU - Specchia, G.

AU - Pastore, D.

AU - Carluccio, P.

AU - Liso, A.

AU - Mestice, A.

AU - Rizzi, R.

AU - Ciuffreda, L.

AU - Pietrantuono, G.

AU - Liso, V.

PY - 2005/12

Y1 - 2005/12

N2 - Relapsed or refractory adult acute lymphoblastic leukemias (ALL) have poor prognosis. The strategy for treating these patients is through reinduction chemotherapy followed by allogeneic stem cell transplantation, provided that the toxicity of the salvage regimen is acceptable. Twenty three patients with relapsed/refractory adult ALL were treated with fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA). Five patients had primary refractory disease, and 18 were in first relapse. Nine (39.1%) patients achieved complete remission (CR) following salvage therapy, whereas 13 (56.5%) patients were refractory, and one patient died in aplasia due to infection. In patients achieving remission, the median time to reach absolute neutrophil count (ANC) more than 0.5×109/l and 1×109/l was 20 (range 16-25) and 24 (range 20-28) days from the start of chemotherapy, respectively. Platelet levels of more than 20×109/l and 100×109/l were achieved in a median time of 23 (range 19-25) and 33 (range 28-39) days, respectively. Fever more than 38.5°C was observed in 18 of 23 patients (78.2%), 13 had fever of unknown origin, and 5 had documented infections. Nonhematological side effects, consisting mainly of mucositis (18/23 or 78.2%) and transient liver toxicity increase (10/23 or 43.4%), were generally tolerated. All nine patients who achieved CR received a second course with FLAG-IDA, and seven patients underwent allogeneic stem cell transplantation (four from a matched donor, one from a mismatched donor, and two from an unrelated donor), while two did not reach that stage due to early relapse from CR. The median overall survival (OS) for all 23 patients was 4.5 (range 1-38) months; for the nine responders, the disease-free survival (DFS) and the OS were 6 (range 3-38) and 9 (7-38) months, respectively; the seven patients who received allogeneic stem cell transplantation had a DFS of 10 (range 7-38) months. In our experience, FLAG-IDA is a well-tolerated regimen in relapsed/refractory ALL patients; the toxicity is acceptable, enabling patients who have achieved CR to receive allogeneic transplantation.

AB - Relapsed or refractory adult acute lymphoblastic leukemias (ALL) have poor prognosis. The strategy for treating these patients is through reinduction chemotherapy followed by allogeneic stem cell transplantation, provided that the toxicity of the salvage regimen is acceptable. Twenty three patients with relapsed/refractory adult ALL were treated with fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA). Five patients had primary refractory disease, and 18 were in first relapse. Nine (39.1%) patients achieved complete remission (CR) following salvage therapy, whereas 13 (56.5%) patients were refractory, and one patient died in aplasia due to infection. In patients achieving remission, the median time to reach absolute neutrophil count (ANC) more than 0.5×109/l and 1×109/l was 20 (range 16-25) and 24 (range 20-28) days from the start of chemotherapy, respectively. Platelet levels of more than 20×109/l and 100×109/l were achieved in a median time of 23 (range 19-25) and 33 (range 28-39) days, respectively. Fever more than 38.5°C was observed in 18 of 23 patients (78.2%), 13 had fever of unknown origin, and 5 had documented infections. Nonhematological side effects, consisting mainly of mucositis (18/23 or 78.2%) and transient liver toxicity increase (10/23 or 43.4%), were generally tolerated. All nine patients who achieved CR received a second course with FLAG-IDA, and seven patients underwent allogeneic stem cell transplantation (four from a matched donor, one from a mismatched donor, and two from an unrelated donor), while two did not reach that stage due to early relapse from CR. The median overall survival (OS) for all 23 patients was 4.5 (range 1-38) months; for the nine responders, the disease-free survival (DFS) and the OS were 6 (range 3-38) and 9 (7-38) months, respectively; the seven patients who received allogeneic stem cell transplantation had a DFS of 10 (range 7-38) months. In our experience, FLAG-IDA is a well-tolerated regimen in relapsed/refractory ALL patients; the toxicity is acceptable, enabling patients who have achieved CR to receive allogeneic transplantation.

KW - Acute lymphoblastic leukemia

KW - FLAG-IDA

KW - Refractory

KW - Relapsed

UR - http://www.scopus.com/inward/record.url?scp=28944449600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28944449600&partnerID=8YFLogxK

U2 - 10.1007/s00277-005-1090-9

DO - 10.1007/s00277-005-1090-9

M3 - Article

VL - 84

SP - 792

EP - 795

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 12

ER -